BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 10574263)

  • 1. Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?
    Linderholm B; Tavelin B; Grankvist K; Henriksson R
    Br J Cancer; 1999 Oct; 81(4):727-32. PubMed ID: 10574263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer.
    Linderholm BK; Lindahl T; Holmberg L; Klaar S; Lennerstrand J; Henriksson R; Bergh J
    Cancer Res; 2001 Mar; 61(5):2256-60. PubMed ID: 11280795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment.
    Linderholm B; Grankvist K; Wilking N; Johansson M; Tavelin B; Henriksson R
    J Clin Oncol; 2000 Apr; 18(7):1423-31. PubMed ID: 10735889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
    Foekens JA; Peters HA; Grebenchtchikov N; Look MP; Meijer-van Gelder ME; Geurts-Moespot A; van der Kwast TH; Sweep CG; Klijn JG
    Cancer Res; 2001 Jul; 61(14):5407-14. PubMed ID: 11454684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment.
    Wu Y; Saldana L; Chillar R; Vadgama JV
    Int J Oncol; 2002 Mar; 20(3):509-16. PubMed ID: 11836562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
    Scorilas A; Talieri M; Ardavanis A; Courtis N; Dimitriadis E; Yotis J; Tsiapalis CM; Trangas T
    Cancer Res; 2000 Oct; 60(19):5427-33. PubMed ID: 11034084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
    Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression of ER beta protein correlates with vascular endothelial growth factor and its prognostic significance in human breast cancer.
    Wen XF; Shen Z; Shen ZZ; Nguyen M; Shao ZM
    Oncol Rep; 2002; 9(5):937-44. PubMed ID: 12168051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up.
    Nakamura Y; Yasuoka H; Tsujimoto M; Yang Q; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K
    Clin Cancer Res; 2003 Feb; 9(2):716-21. PubMed ID: 12576440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locoregional failure 15 years after mastectomy in women with one to three positive axillary nodes with or without irradiation the significance of tumor size.
    Fodor J; Polgár C; Major T; Németh G
    Strahlenther Onkol; 2003 Mar; 179(3):197-202. PubMed ID: 12627264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
    Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
    J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Local relapse in young (< or = 40 years) women with breast cancer after mastectomy or breast conserving surgery: 15-year results].
    Fodor J; Mózsa E; Zaka Z; Polgár C; Major T
    Magy Onkol; 2005; 49(3):203, 205-8. PubMed ID: 16249814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF.
    Sanchez BC; Sundqvist M; Fohlin H; Spyratos F; Nordenskjöld B; Stål O; Linderholm BK
    Eur J Cancer; 2010 Jun; 46(9):1580-7. PubMed ID: 20413297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of the prognostic significance of vascular endothelial growth factor in node positive primary breast carcinoma.
    MacConmara M; O'Hanlon DM; Kiely MJ; Connolly Y; Jeffers M; Keane FB
    Int J Oncol; 2002 Apr; 20(4):717-21. PubMed ID: 11894115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy.
    Truong PT; Yong CM; Abnousi F; Lee J; Kader HA; Hayashi A; Olivotto IA
    J Am Coll Surg; 2005 Jun; 200(6):912-21. PubMed ID: 15922205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer.
    Linderholm BK; Gruvberger-Saal S; Fernö M; Bendahl PO; Malmström P
    Breast; 2008 Oct; 17(5):484-91. PubMed ID: 18508268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.